Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: erickerickson who wrote (46022)	5/9/2018 11:57:58 AM
From: plhky3465	Respond to of 63283

thx. i forgot about todays Conf call

To: erickerickson who wrote (46022)	5/9/2018 3:20:34 PM
From: Fitzhughlaw	13 Recommendations Recommended By btlbail1 captcobra1 corndog erippetoe ladyPI and 8 more members Read Replies (2) \| Respond to of 63283

"PPS catalyst the day it's announced? Not really. Perhaps increasing 60+ days later... ." Strongly disagree, and don't assess that it's "baked in" now. On February 7, the PPS closed at $16.52, and on the 8th, the company announced that the filing would be pushed back to May; the stock closed at $15.11 and drifted down to as low as $14.06 on the 9th. Even at its current price it is 15% to 25% below the covering analysts' price targets. Even with what we and others anticipate to be some compelling data at ASCO, the street wants to see the ball advanced on commercialization efforts, and that's the filing of the BLA. Don't get me wrong - I'm glad to think that some more data might continue to be a harbinger for the dreaded "p word" [potential], but at this point, once the BLA is filed, it's a signal of execution on bringing a product to market. Right now, the company's valuation has been premised on its having competent management, but the next catalyst will have to be a demonstration that they can execute on the commercialization front. I believe that given the short position, the filing of the BLA alone is good for $3.50 to $4 per share over the next two trading days, and again that would get us merely to the analysts' price targets, which are notoriously conservative given that group's typical modus operandi. MAF